A phase III, multi-center, open-label, controlled, randomized study to evaluate the immunogenicity, safety, tolerability and the ability to prime for memory of Chiron meningococcal C conjugate vaccine when administered to healthy infants as one dose given at 2 or 6 months of age with a booster at 12-16 months of age, in comparison to two doses in the first year of life, given two months apart, with a booster at 12-16 months of age; and in comparison to one dose given at 12-16 months of age.

Trial Profile

A phase III, multi-center, open-label, controlled, randomized study to evaluate the immunogenicity, safety, tolerability and the ability to prime for memory of Chiron meningococcal C conjugate vaccine when administered to healthy infants as one dose given at 2 or 6 months of age with a booster at 12-16 months of age, in comparison to two doses in the first year of life, given two months apart, with a booster at 12-16 months of age; and in comparison to one dose given at 12-16 months of age.

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Feb 2012

At a glance

  • Drugs Meningococcal vaccine group C conjugate (Primary)
  • Indications Meningococcal group C infections
  • Focus Pharmacodynamics
  • Sponsors Chiron Corporation; Novartis
  • Most Recent Events

    • 19 Apr 2011 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 14 May 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top